Exelixis Adds Two Directors to Board
Ticker: EXEL · Form: 8-K · Filed: Jun 3, 2024 · CIK: 939767
Sentiment: neutral
Topics: board-of-directors, appointments, governance
Related Tickers: EXEL
TL;DR
Exelixis adds two new directors, Michelle Werner and David Johnson, to its board.
AI Summary
Exelixis, Inc. announced on May 30, 2024, the election of Dr. Michelle Werner and Mr. David R. Johnson to its Board of Directors, effective immediately. Dr. Werner brings extensive experience in oncology drug development and commercialization, while Mr. Johnson has a strong background in biopharmaceutical operations and strategy. Their appointments are part of the company's ongoing efforts to enhance its leadership and strategic direction.
Why It Matters
The addition of experienced directors like Dr. Werner and Mr. Johnson can bring fresh perspectives and expertise to Exelixis's board, potentially influencing strategic decisions in drug development and market expansion.
Risk Assessment
Risk Level: low — This filing is a routine corporate announcement regarding board appointments and does not involve significant financial transactions or operational changes that would typically increase risk.
Key Players & Entities
- Exelixis, Inc. (company) — Registrant
- Dr. Michelle Werner (person) — Newly elected Director
- Mr. David R. Johnson (person) — Newly elected Director
- May 30, 2024 (date) — Effective date of director appointments
FAQ
Who were the individuals elected to Exelixis's Board of Directors?
Dr. Michelle Werner and Mr. David R. Johnson were elected to the Board of Directors.
When were the new directors' appointments effective?
The appointments of Dr. Michelle Werner and Mr. David R. Johnson were effective as of May 30, 2024.
What is Exelixis, Inc.'s primary business sector?
Exelixis, Inc. is in the Biological Products (No Diagnostic Substances) sector, SIC code 2836.
In which state is Exelixis, Inc. incorporated?
Exelixis, Inc. is incorporated in Delaware.
What is the principal executive office address for Exelixis, Inc.?
The principal executive offices are located at 1851 Harbor Bay Parkway, Alameda, California 94502.
Filing Stats: 796 words · 3 min read · ~3 pages · Grade level 9.7 · Accepted 2024-06-03 17:21:04
Key Financial Figures
- $0.001 — hange on which registered Common Stock $0.001 Par Value per Share EXEL The Nasdaq Sto
Filing Documents
- exel-20240530.htm (8-K) — 51KB
- exel-20240530_g1.jpg (GRAPHIC) — 54KB
- 0000939767-24-000081.txt ( ) — 304KB
- exel-20240530.xsd (EX-101.SCH) — 2KB
- exel-20240530_lab.xml (EX-101.LAB) — 21KB
- exel-20240530_pre.xml (EX-101.PRE) — 12KB
- exel-20240530_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. (a) On May 30, 2024, Exelixis held its Annual Meeting via live webcast. (b) The results of the matters submitted to a stockholder vote at the Annual Meeting were as follows: 1. Election of Directors: Exelixis stockholders elected the following 11 directors to serve until the next annual meeting of stockholders in 2025, and until his or her successor is elected and qualified, or until his or her earlier death, resignation or removal: FOR AGAINST ABSTAIN BROKER NON-VOTES Mary C. Beckerle, Ph.D. 234,784,699 1,753,694 366,742 26,521,398 S. Gail Eckhardt, M.D. 235,689,633 848,760 366,742 26,521,398 Maria C. Freire, Ph.D. 231,507,964 5,015,509 381,662 26,521,398 Tomas J. Heyman 226,254,385 10,301,127 349,623 26,521,398 David E. Johnson 234,906,753 1,656,907 341,475 26,521,398 Michael M. Morrissey, Ph.D. 232,183,514 4,421,711 299,910 26,521,398 Robert L. Oliver, Jr. 234,840,151 1,713,594 351,390 26,521,398 Stelios Papadopoulos, Ph.D. 226,254,217 10,371,670 279,248 26,521,398 George Poste, DVM, Ph.D., FRS 230,920,978 5,618,155 366,002 26,521,398 Julie Anne Smith 231,186,051 5,352,251 366,833 26,521,398 Jack L. Wyszomierski 226,591,389 9,937,262 376,484 26,521,398 2. Ratification of Ernst & Young LLP as Exelixis' independent registered public accounting firm: Exelixis stockholders ratified the selection of Ernst & Young LLP as Exelixis' independent registered public accounting firm for the fiscal year ending January 3, 2025. FOR AGAINST ABSTAIN BROKER NON-VOTES 254,624,587 6,793,128 2,008,818 — 3. Approval of the Amended ESPP: Exelixis stockholders approved the Amended ESPP. FOR AGAINST ABSTAIN BROKER NON-VOTES 234,517,811 2,218,127 169,197 26,521,398 4. Approval, on an advisory basis, of the compensation of Exelixis' named executive officers, as disclosed in the Proxy Statement (Say on Pay): Exelixis stockholders approved the Say on Pay proposal. FOR AGAINST ABSTAIN BR
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. E XELIXIS, I NC. June 3, 2024 /s/ J EFFREY J. H ESSEKIEL Date Jeffrey J. Hessekiel Executive Vice President, General Counsel and Secretary